Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. (Q45991042)
Jump to navigation
Jump to search
scientific article published in July 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. |
scientific article published in July 2009 |
Statements
1 reference
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. (English)
1 reference
Asher Chanan-Khan
1 reference
Kena C Miller
1 reference
Laurie Musial
1 reference
Swaminathan Padmanabhan
1 reference
Jihnhee Yu
1 reference
Sikander Ailawadhi
1 reference
Taimur Sher
1 reference
Alice Mohr
1 reference
Zale P Bernstein
1 reference
Maurice Barcos
1 reference
Mehul Patel
1 reference
Dan Iancu
1 reference
Kelvin Lee
1 reference
Myron S Czuczman
1 reference
1 July 2009
1 reference
1 reference
50
1 reference
7
1 reference
1096-1101
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference